Tech Transfer eNews Blog

Mahana Therapeutics licenses digital irritable bowel syndrome tech from King’s College London

By Jesse Schwartz
Published: January 15th, 2020

Digital therapeutics company Mahana Therapeutics has entered into a licensing and collaboration agreement with King’s College London to commercialize a digital treatment for irritable bowel syndrome (IBS).

The licensed technology is a web-based cognitive behavioral therapy (CBT) treatment that, according to researchers at King’s College London, significantly decreases the severity of IBS symptoms and is more effective than typical treatments. They also say the technology reduces anxiety and depression in patients over three, six and 12-month time periods.

“The digital era has allowed us the opportunity to explore new ways to reach patients and provide them with access to psychological-based therapies that help control symptoms in a more convenient way,” says Rona Moss-Morris, researcher at King’s and co-developer of the technology.

“We are thrilled to partner with Mahana Therapeutics,” she adds. “Mahana shares our vision to provide patients in the UK and abroad with clinically and cost-effective treatments for gastrointestinal diseases, and they have been an amazing collaborative partner.”

Robert Paull, co-founder and CEO of Mahana, comments, “This is the perfect union of our vision at Mahana plus a leading academic institution’s desire to bring world-leading research into the hands of patients. The digital therapeutic developed by professor Moss-Morris and her colleagues at King’s College London is best-in-class and supported by extensive clinical data. We are excited to bring this important treatment option to patients in the United Kingdom, United States, and globally.”

Source: Herald-Mail Media

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment